AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Matinas Biopharma Plunges 14.83% After Warrant Exchange
Generated by AI AgentAinvest Pre-Market Radar
Monday, Aug 18, 2025 7:50 am ET1min read
Aime SummaryOn August 18, 2025, Matinas Biopharma's stock experienced a significant drop of 14.83% in pre-market trading, marking a notable decline in its share price.
Matinas Biopharma recently exchanged warrants for 466,666 shares of its common stock. This move involved canceling an equal number of warrants, each previously exercisable at $17.50 per share. The exchange was completed on August 15, 2025, and the warrants were issued on April 5, 2024. This action was done in reliance on an exemption from registration provided by Section 3(a)(9) of the Securities Act of 1933.
Additionally,
Holdings Inc. performed a 1 for 50 consolidation. This means that holders of the company's stock will now hold 1 share for every 50 shares they previously owned. This consolidation is a corporate action that can impact the stock's liquidity and trading dynamics.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Esperion Therapeutics shares plunge 5.14% on Dec. 31 2025 due to regulatory and pipeline shifts
Dec.31 2025
Ses AI (NYSE: SES) plunges 6.28% as investors unwind holiday-driven rally gains amid mixed corporate signals.
Dec.31 2025
Novabay Pharmaceuticals Inc (NBY) Surges 27.57% in Pre-Market on December 31 as Small-Cap Biopharma Gains Lead
Dec.31 2025
Dingdong (Cayman) shares plunge 7.09% amid mixed earnings and strategic shifts
Dec.31 2025
Flushing Financial Corp. Plunges 8.94% Amid Renewed Merger Scrutiny
Dec.31 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet